Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy-associated solid tumors.

Lois B Travis1

  • 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA. travisl@mail.nih.gov

Acta Oncologica (Stockholm, Sweden)
|September 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort study.

EClinicalMedicine·2026
Same author

Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World Setting.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Cardiovascular disease risk among long-term testicular cancer survivors following contemporary cisplatin-based chemotherapy.

Journal of the National Cancer Institute·2026
Same author

Comparison of associations suggests mainly distinct pools of genetic risk factors contribute to cisplatin-induced hearing loss and hearing difficulty in the general population.

Frontiers in pharmacology·2025
Same author

Impact of Population Pharmacogenomics on Cisplatin-Induced Neurotoxicities in Testicular Cancer Survivors.

Cancer medicine·2025
Same author

Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancer.

Journal of the National Cancer Institute·2025
Same journal

Overall survival following palliative immune checkpoint inhibitor treatment according to ECOG performance status: a large registry-based study.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

Pathological characteristics and prognosis of very young patients with early breast cancer: a comparative analysis with older patients.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

Recent survival trends in the most fatal cancers in the Nordic countries: gains in some but not in all.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

First-in-human quantitative [¹⁵O]H₂O PET imaging of tumour blood flow at rest and during exercise in lymphoma patients.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

Starshot field configuration in the linac isocentre size determination: a comparison of film and electronic portal imaging device measurements.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

Perspectives on artificial intelligence-generated chronic disease risk predictions in early breast cancer: an international survey among radiation oncologists.

Acta oncologica (Stockholm, Sweden)·2026
See all related articles

Cancer survivors face risks of secondary cancers from radiation and chemotherapy. However, the benefits of cancer treatments significantly outweigh these risks, improving overall survival.

Area of Science:

  • Oncology
  • Cancer Survivorship Research
  • Medical Treatment Side Effects

Background:

  • Improving cancer survival rates necessitate understanding long-term treatment effects.
  • Second malignant neoplasms (SMNs) are a critical late sequela of cancer therapy.
  • Solid tumors are an increasing concern among cancer survivors, alongside secondary leukemia.

Purpose of the Study:

  • To review recent developments in treatment-associated solid malignancies.
  • To emphasize the role of radiotherapy and chemotherapy in adult secondary cancers.
  • To identify future research directions in cancer therapy-induced solid tumors.

Main Methods:

  • Review of current literature on radiotherapy and chemotherapy-induced solid tumors.
  • Analysis of risk factors and etiologic influences for second cancers.

Related Experiment Videos

  • Focus on adult populations and clinical management implications.

    • Main Results:

    • Solid tumors represent a significant burden in some cancer survivor populations.
    • Distinguishing therapy-induced cancers from other etiologies is complex.
    • Quantifying second cancer risk aids in balancing treatment efficacy and sequelae.

    Conclusions:

    • Cancer therapies, while carrying risks of secondary malignancies, are largely responsible for improved survival.
    • The benefits of cancer treatments generally outweigh the risks of developing a second cancer.
    • Further research is needed to better manage and mitigate risks associated with cancer therapy.